⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BFRIW News
Biofrontera Inc. Warrants
Form 8-K
sec.gov
BFRI
BFRIW
Form 8-K
sec.gov
BFRIW
BFRI
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
globenewswire.com
BFRI
BFRIW
Form 8-K
sec.gov
BFRIW
BFRI
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
globenewswire.com
BFRI
BFRIW
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
globenewswire.com
BFRI
BFRIW
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
globenewswire.com
BFRI
BFRIW
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
globenewswire.com
BFRI
BFRIW